IMMUNOSCORE® for
Colon Cancer

Designed to deliver critical information to guide chemotherapy decision-making, Immunoscore® can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in Stage III localized colon cancer to inform them about the optimal treatment duration for their patients.

colon-cancer-logo

For healthcare professionals

How IMMUNOSCORE® for Colon Cancer works

By providing an accurate measurement of T lymphocyte infiltration into the tumor, Immunoscore® gives healthcare providers insight into the risk of relapse.

A low Immunoscore® means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, a high Immunoscore® means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Clinical Validation and Utility

Enabling physicians to devise treatment plans that maximize clinical benefit while minimizing toxicity

Immunoscore® for colon cancer assesses the patient’s immune response at the tumor site to refine the patient’s risk profile and develop an optimized treatment plan that minimizes exposure to potentially toxic chemotherapy.

Immunoscore® has been validated in an international study conducted on more than 2,500 Stage I-III colon cancer patients [1]. This study showed that Immunoscore® is a powerful and independent prognostic factor for patient survival which provided the greatest contribution to patient prognostication of all assessed factors. In validation studies of stage III colon cancers, only Immunoscore® High patients experienced a significant therapy benefit.

In 2020, Immunoscore® was included in the ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Colon Cancer and the World Health Organization (WHO), in its latest edition of the Digestive System Tumours, cited immune response as an essential and desirable diagnostic criterion for colorectal cancer, in addition to traditional histological parameters*.

*The World Health Organization is not endorsing the Immunoscore® commercial assay.

47%

relative contribution of Immunoscore to survival prediction, compared to 28% relative contribution of AJCC/UICC TNM staging

Managing patients with localized colon cancer

IMMUNOSCORE®
for stage ii cc patients

In stage II colon cancer, Immunoscore® can identify a large subset of patients (70%) that are classified as high-risk by TNM staging but whose actual risk of relapse is similar to that of low-risk patients. These patients can potentially be spared adjuvant chemotherapy and the associated toxicities[2].

70%

of patients classified as clinically high risk actually have the same risk of relapse as low-risk patients when Immunoscore is High.

Untreated patients with stage II cancer stratified by clinico-pathologic risk and Immunosocre.

Untreated patients with stage II cancer (n = 1,130) stratified by clinico-pathologic risk and Immunoscore®.

70%

of patients classified as clinically high risk actually have the same risk of relapse as low-risk patients when Immunoscore is High.

IMMUNOSCORE®
for stage iii cc patients

In Stage III colon cancer, Immunoscore® informs about the optimal duration of FOLFOX treatment, maximizing the benefit-risk balance by avoiding unnecessary exposure to chemotherapy associated toxicities.

50%

of patients benefit the most from full chemotheropy duration

Immunoscore identifies which patients can benefit from 6-months of FOLFOX treatment

Disease-free survival of patients with Stage III colon cancer and Immunoscore® High treated for either 6 months (n = 275, darker line) or 3 months (n = 275, lighter line) with FOLFOX.

50%

of patients benefit the most from full chemotheropy duration

Interpreting the IMMUNOSCORE®

Immunoscore predicts the risk of relapse

Immunoscore® values are reported based on pre-defined cut-offs in categorical scores (IS 0 to 4) and in 2 categories of recurrence risk: a higher Immunoscore® is associated with a lower risk of recurrence[1, 3-4]. Based on the result of this recurrence risk, physicians have the possibility to implement a personalized management for their patients, including both TNM staging and Immune parameters.

Immunoscore predicts the risk of relapse

Frequently Asked Questions

Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of localized colon cancer. The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.

For localized colon cancer, in combination with standard clinicopathologic features, the Immunoscore® result is indicated as an aid to determine the risk of recurrence and to adjust adjuvant chemotherapy decision-making for patients with early-stage colon cancer.

As soon as the sample is received in our laboratories, it will take no more than 10 working days to provide you with the result.

"I would recommend Immunoscore® because it is easy to implement in the clinical practice and helps to stratify the right patient for the right duration of chemotherapy"

Dr. Matin Mellor Abdullah

Malaysia

Interested in ordering A test?

Select your Country

We have different programs available. Please fill in the form below to get further information.

Contact Form




    You provided us with email information that we will use to contact you about our products and services. The information will not be sold to any third party. Veracyte may transfer your personal information to our CRM systems solely for the purposes of data hosting, marketing actions and to our distributor partners for commercial activity.

    You may unsubscribe at any time by sending an email at privacy@haliodx.com. For information on our privacy practices and commitment to protecting your privacy, please review our Privacy policy.

    our programs

    "Immunoscore® for Colon Cancer is also available through our Decision Impact Program. Please fill in the contact form for further information."

    Veracyte delivers Immunoscore®️ results worldwide from their CLIA laboratories. The Immunoscore and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA

    our programs

    "IMMUNOSCORE® for Colon Cancer is available through our access programs. Please fill in the above contact form for further information."

    Veracyte delivers Immunoscore®️ results worldwide from their CLIA laboratories. The Immunoscore and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA

    Step 1: Obtain specimen collection kits

    You can request a kit by sending us a request

    • By contacting your sales representative.
    • By sending us a request

    Please be sure to include the address for the laboratory where the patient’s specimen is stored so we can send the kit to the correct location.

    step_1_img@2x

    Step 2: Complete all documents provided within the collection kit

    Please be sure to supply all of the requested information on the forms that are included in the specimen collection kit, including the test requisition form (TRF). Make sure your patient has signed the Assignment of Benefit (AoB) form.

    You can also download the necessary information using the link below:

    To request the AoB form, please contact your sales representative.

    step2

    Step 3: Prepare and send the patient sample

    Veracyte can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from the primary tumor surgical resection of patients with localized colon cancer and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the following downloadable document:

    Sample Preparation Instructions

    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to Veracyte following the instructions provided with the kit.

    shipment-@2x

    Step 4: Access your IMMUNOSCORE Results

    The turnaround time for Immunoscore® testing is a maximum of 10 working days. Turnaround time is considered from the day the specimen is received at our laboratory to the time the test is reported to the ordering physician.

    You will receive the Immunoscore® results by email.

    You can also directly log in to the Oncology Portal to get the results.

    step4

    Step 1: Obtain specimen collection kits

    You can request a kit by sending us a request

    Please be sure to include the address for the laboratory where the patient’s specimen is stored so we can send the kit to the correct location.

    step_1_img@2x

    Step 2: Complete all documents provided within the collection kit

    Please be sure to supply all of the requested information on the forms that are included in the specimen collection kit, including the test requisition form (TRF).

    You can also download the necessary information using the link below:

    For Latin America and Canada, download this Test Request Form.

    step2

    Step 3: Prepare and send the patient sample

    Veracyte can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from the primary tumor surgical resection of patients with localized colon cancer and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the following downloadable document:

    Sample Preparation Instructions

    For Latin America and Canada, download these Sample Preparation Instructions.

    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to Veracyte following the instructions provided with the kit.

    shipment-@2x

    Step 4: Access your IMMUNOSCORE Results

    The turnaround time for Immunoscore® testing is a maximum of 10 working days. Turnaround time is considered from the day the specimen is received at our laboratory to the time the test is reported to the ordering physician.

    You will receive the Immunoscore® results by email.

    You can also directly log in to the Oncology Portal to get the results.

    step4

    Step 1: Obtain specimen collection kits

    You can request a kit by sending us a request

    Please be sure to include the address for the laboratory where the patient’s specimen is stored so we can send the kit to the correct location.

    step_1_img@2x

    Step 2: Complete all documents provided within the collection kit

    Please be sure to supply all of the requested information on the forms that are included in the specimen collection kit, including the test requisition form (TRF).

    step2

    Step 3: Prepare and send the patient sample

    Veracyte can work directly with the pathology team and treating physician to facilitate specimen collection.

    The tissue specimen should be from the primary tumor surgical resection of patients with localized colon cancer and not from a site of metastasis. You can send either an FFPE tumor block or 4 µm unstained slides from an FFPE block (6 slides required per test).

    To prepare the patient specimen, follow the instructions in the Sample Preparation Instructions provided within the kit.

    Once the sample is prepared and placed in the specimen collection kit along with the required documentation, return the kit to Veracyte following the instructions provided with the kit.

    shipment-@2x

    Step 4: Access your IMMUNOSCORE Results

    The turnaround time for Immunoscore® testing is a maximum of 10 working days. Turnaround time is considered from the day the specimen is received at our laboratory to the time the test is reported to the ordering physician.

    You will receive the Immunoscore® results by email.

    You can also directly log in to the Oncology Portal to get the results.

    step4

    Veracyte delivers Immunoscore®️ results worldwide from their CLIA laboratories.

    Immunoscore®️ is CE-IVD marked.
    The Immunoscore and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA.

    Top Resources for healthcare professionals

    Contact Our Team to Inquire About IMMUNOSCORE®

    Distributors and Commercial Team Page

    References

    1. Pagès F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128-2139.
    2. Galon J, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019. 37:4_suppl, 487-487.
    3. Sinicrope, et al. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectr. 2020 Apr 5;4(3):pkaa023.
    4. Pagès F, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020 Jul;31(7):921-929.
    5. Mlecnik B, et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol. 2020 Nov 1;38(31):3638-3651.